NASDAQ:ANIK - Anika Therapeutics Stock Price, Forecast & News

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Anika Therapeutics Inc (NASDAQ:ANIK) posted its earnings results on Thursday, October, 24th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.39 by $0.25. The biotechnology company earned $29.70 million during the quarter, compared to the consensus estimate of $27.01 million. Anika Therapeutics had a net margin of 27.60% and a return on equity of 11.59%. The firm's quarterly revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.53 earnings per share. View Anika Therapeutics' Earnings History.

Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Anika Therapeutics.

5 analysts have issued 1-year price targets for Anika Therapeutics' shares. Their forecasts range from $29.00 to $65.00. On average, they anticipate Anika Therapeutics' share price to reach $53.25 in the next year. This suggests a possible upside of 16.5% from the stock's current price. View Analyst Price Targets for Anika Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 sell rating, 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Anika Therapeutics.

Headlines about ANIK stock have been trending somewhat positive this week, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Anika Therapeutics earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Anika Therapeutics.

Some companies that are related to Anika Therapeutics include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Antares Pharma (ATRS), Cerus (CERS), OraSure Technologies (OSUR) and Meridian Bioscience (VIVO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Gilead Sciences (GILD), Alibaba Group (BABA), Celgene (CELG), Broadcom (AVGO), AT&T (T), Skyworks Solutions (SWKS), Enterprise Products Partners (EPD), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC) and GW Pharmaceuticals PLC- (GWPH).

Anika Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Boston Trust Walden Corp (1.54%), Assenagon Asset Management S.A. (0.10%), State of Alaska Department of Revenue (0.08%) and Welch & Forbes LLC (0.03%). Company insiders that own Anika Therapeutics stock include Glenn R Larsen, Jeffery S Thompson, Joseph G Darling, Joseph L Bower, Raymond J Land and Sylvia Cheung. View Institutional Ownership Trends for Anika Therapeutics.

ANIK stock was sold by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp. Company insiders that have sold Anika Therapeutics company stock in the last year include Glenn R Larsen, Jeffery S Thompson, Joseph L Bower, Raymond J Land and Sylvia Cheung. View Insider Buying and Selling for Anika Therapeutics.

ANIK stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Welch & Forbes LLC and State of Alaska Department of Revenue. View Insider Buying and Selling for Anika Therapeutics.

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANIK stock can currently be purchased for approximately $45.71.

Anika Therapeutics has a market capitalization of $652.24 million and generates $105.56 million in revenue each year. The biotechnology company earns $18.72 million in net income (profit) each year or $1.84 on an earnings per share basis. Anika Therapeutics employs 133 workers across the globe.View Additional Information About Anika Therapeutics.

The official website for Anika Therapeutics is http://www.anikatherapeutics.com/.

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]